Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint

Excessive collagen deposition by fibroblasts surrounding some tumors has seriously limited the efficacy of checkpoint inhibitor therapies. Chen et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210693) show that IL-17 promotes collagen deposition by cancer-associated fibroblasts, enhancing im...

Descripción completa

Detalles Bibliográficos
Autor principal: McGeachy, Mandy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121177/
https://www.ncbi.nlm.nih.gov/pubmed/35583818
http://dx.doi.org/10.1084/jem.20220444
_version_ 1784711099844657152
author McGeachy, Mandy J.
author_facet McGeachy, Mandy J.
author_sort McGeachy, Mandy J.
collection PubMed
description Excessive collagen deposition by fibroblasts surrounding some tumors has seriously limited the efficacy of checkpoint inhibitor therapies. Chen et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210693) show that IL-17 promotes collagen deposition by cancer-associated fibroblasts, enhancing immune exclusion of tumors, and that targeting IL-17–triggered HIF1α expression can reverse matrix mediated immune exclusion.
format Online
Article
Text
id pubmed-9121177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-91211772022-11-18 Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint McGeachy, Mandy J. J Exp Med Insights Excessive collagen deposition by fibroblasts surrounding some tumors has seriously limited the efficacy of checkpoint inhibitor therapies. Chen et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210693) show that IL-17 promotes collagen deposition by cancer-associated fibroblasts, enhancing immune exclusion of tumors, and that targeting IL-17–triggered HIF1α expression can reverse matrix mediated immune exclusion. Rockefeller University Press 2022-05-18 /pmc/articles/PMC9121177/ /pubmed/35583818 http://dx.doi.org/10.1084/jem.20220444 Text en © 2022 McGeachy https://creativecommons.org/licenses/by-nc-sa/4.0/http://www.rupress.org/terms/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
McGeachy, Mandy J.
Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title_full Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title_fullStr Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title_full_unstemmed Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title_short Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint
title_sort matrix reboot: il-17 signals cafs to create a second tumor t cell checkpoint
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121177/
https://www.ncbi.nlm.nih.gov/pubmed/35583818
http://dx.doi.org/10.1084/jem.20220444
work_keys_str_mv AT mcgeachymandyj matrixrebootil17signalscafstocreateasecondtumortcellcheckpoint

Ejemplares similares